TTOO Stock Alert: T2 Biosystems Seeks Approval for Reverse Stock Split

Advertisement

  • T2 Biosystems (TTOO) has proposed a reverse stock split in a range between 1-for-50 and 1-for-150.
  • The company has a deadline of Nov. 20 for its stock to close above $1 for at least 10 consecutive business days.
  • TTOO stock is down by more than 60% this year.
TTOO stock - TTOO Stock Alert: T2 Biosystems Seeks Approval for Reverse Stock Split

Source: AnaLysiSStudiO / Shutterstock.com

On Sept. 12, T2 Biosystems (NASDAQ:TTOO) will hold its annual meeting of stockholders. Up for vote are a total of nine proposals, which include a reverse stock split in a range between 1-for-50 and 1-for-150. If approved, the final reverse split ratio will be chosen by T2’s board of directors. TTOO stockholders will have until Sept. 11 at 11:59 p.m. Eastern to cast their votes.

Shares of TTOO are currently trading below $1, which is in violation of Nasdaq’s minimum price requirement of $1. To regain compliance, TTOO must close above $1 for at least 10 consecutive business days. Generally, shares are not required to trade above this level for more than 20 consecutive business days. A reverse stock split would help the company regain the $1 threshold, as it would consolidate shares, increasing the stock price in the process.

TTOO Stock: T2 Proposes Reverse Stock Split

Earlier this month, the company regained compliance with Nasdaq’s market value of listed securities (MVLS) requirement. T2 was previously in noncompliance because its MVLS fell below $35 million for 30 consecutive business days. As of Aug. 7, T2’s MVLS had traded for at least $35 million for 10 consecutive business days, satisfying Nasdaq’s requirement.

Another proposal to watch during the upcoming meeting will be proposal two. The proposal seeks approval for the election of Jack Cumming and David Elsbree as Class III directors until at least 2026. Other proposals relate to executive officer compensation, the 2014 employee stock purchase plan, the ratification of BDO as T2’s independent registered public accounting firm, and the approval of the CRG debt to equity conversion.

Meanwhile, the company recently reported its second-quarter earnings. Revenue tallied in at just $1.96 million compared to $5.91 million a year ago, showing a significant decline of 66.8%. This was primarily due to a slowdown in product revenue and $0 in contribution revenue compared to $3.35 million year-over-year (YOY). Contribution revenue totaled $0.4 million for the six months ended June 30, amounting to a YOY decrease of $6.3 million “due to timing of the contract activity and less option amount available under Option 3, which was available for the first quarter of 2023, compared to Option 2A, which was available for the first quarter of 2022.”

Still, T2’s net loss shrunk to $6.34 million compared to $18.03 million a year ago. This was due to lower shipping, service and repair costs, and lower consumable sales of T2SARS-CoV-2.

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.

Read More:Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, Eddie Pan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.


Article printed from InvestorPlace Media, https://investorplace.com/2023/08/ttoo-stock-alert-t2-biosystems-seeks-approval-for-reverse-stock-split/.

©2024 InvestorPlace Media, LLC